Axa
SWTX

Axa’s SpringWorks Therapeutics SWTX Stock Holding History

Axa’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-107,022
Closed -$2.63M – 1203
2022
Q2 		$2.63M Sell
107,022
-2,079
-2% -$76K 0.01% 726
2022
Q1 		$6.16M Buy
109,101
+1
+0% +$57 0.02% 590
2021
Q4 		$6.76M Buy
109,100
+1,304
+1% +$86.3K 0.02% 588
2021
Q3 		$6.84M Buy
107,796
+3,972
+4% +$306K 0.02% 598
2021
Q2 		$8.56M Sell
103,824
-7,885
-7% -$599K 0.02% 558
2021
Q1 		$8.22M Buy
+111,709
New +$8.75M 0.03% 561

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Axa's SWTX Position: Q3 2022 in Review

Axa sold out of SpringWorks Therapeutics (SWTX) in Q3 2022, closing a stake of 107,022 shares — an estimated $2.63M sold.

Axa first reported a position in SWTX in Q1 2021 and held it in 6 quarters. The position peaked at $8.56M in Q2 2021. 148 funds tracked by Wall St. Rank hold SWTX as of Q3 2022.

  • Axa reported no remaining SpringWorks Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Axa sold 107,022 SpringWorks Therapeutics shares in Q3 2022, an estimated $2.63M.
  • Axa first reported a position in SpringWorks Therapeutics in Q1 2021 and held it in 6 quarters.
  • Axa's SpringWorks Therapeutics position peaked at $8.56M in Q2 2021.
  • 148 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2022.

Based on Axa's 13F filing for Q3 2022, filed 14 Nov 2022.